ARCHIVES

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Gets $937 Million For FY 79 As Congress Adjourns; Cancer Act Renewed For Two Years

October 20, 1978

Center Directors To Rewrite 5-Year Plan With Little Staff Help

March 9, 1990

Cullen Credits Staff With Success Of STCP, Strong Prevention Program a NCI

May 19, 1989

Massive New Radiation Research program Costing From $300-$400 Million Over 10 Years Suggested

February 11, 1977

In Brief: Three Centers Win Comprehensive Designation; Hiatt Named Deputy Director, NCI Cancer Control

October 31, 1997

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012